DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Duchenne Muscular Dystrophy
  4. Research Highlights/News
  5. 2017 Duchenne Muscular Dystrophy Research Program

Duchenne Muscular Dystrophy

NEWS RELEASE

Released: March 31, 2017

Defense Health Program
Department of Defense Duchenne Muscular Dystrophy Research Program
Anticipated Funding Opportunities for Fiscal Year 2017 (FY17)

Due to the current Continuing Resolution, the FY17 Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP), the DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

FY17 DMDRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the DMDRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

All applications for the FY17 DMDRP funding opportunities are required to address at least one of the following Focus Areas:

  • Cardiac studies, including identifying mechanisms of pathology and therapeutic interventions
  • Clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve clinical care and quality of life in areas such as:
    • Cognitive function
    • Endocrinology
    • Gastrointestinal issues
    • Immunology
    • Orthopaedics
    • Psychosocial issues
    • Pulmonology (including sleep-focused studies)
    • Skeletal muscle
  • Assessment of clinical trial tools and outcome measures, such as:
    • Discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers
    • Novel clinical outcome assessments
    • Patient-centered outcomes, e.g., quality of life, activities of daily living
    • Potential surrogate markers
  • Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (including drug exposure, independent replication, and comparative studies)

Award Mechanism Eligibility Key Mechanism Elements Funding
Investigator-Initiated Research Award Principal Investigator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Optional Nested Resident or Medical Student Trainee: Resident trainee must be enrolled in an accredited residency program. Medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school. Trainees must be able to devote a minimum of 40% level of effort.

Optional Multidiscipline Collaborator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
  • Supports translational research that will have an impact on improving the function, quality of life, and/or extending the lifespan for all individuals with Duchenne.
  • Supports translational research that will accelerate the movement of promising new ideas in Duchenne research into clinical applications
  • Optional Multidiscipline Collaboration:
    Supports projects that include multi-disciplinary collaborations including, but not limited to, the following: immunology, nanotechnology, or orthopaedics.
    Applications that include a Multidiscipline Collaborator who meets criteria identified in the Program Announcement/Funding Opportunity may apply for a higher level of funding.
  • Clinical trials are allowed.
  • Preliminary data are required.
  • Maximum funding of $600,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Nested traineeship:
    Additional maximum of $50,000 for residents or $30,000 for medical students in direct costs (plus indirect costs) over a one-year period of performance.
  • Optional Multidiscipline Collaboration: Additional maximum of $150,000 in direct costs over the 3-year period of performance.
Career Development Award Principal Investigator: Must be research (Ph.D.) or physician (M.D.) scientists at an early stage of their research careers with a minimum of 2 years post terminal degree (excluding medical residency or family medical leave), working to become independent investigators who exhibit a strong desire to pursue careers in Duchenne research.

Mentor: Must hold a position at or above the level of an Associate Professor (or equivalent).
  • Supports early-career investigators to conduct impactful research under the mentorship of an experienced muscular dystrophy researcher.
  • Clinical trials are not allowed.
  • Preliminary data are required.
  • Maximum funding of $275,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Thursday, May 26, 2022